Vitals & Signals
The FDA is quietly rewriting the fundamental contract of clinical AI regulation — moving from a pre-market permission slip to a post-market surveillance regime — and every founder, investor, and clinician in this industry needs to understand what that means before the framework lands.
6 Folgen
Kommentare
0Sei die erste Person, die kommentiert
Melde dich jetzt an und werde Teil der Vitals & Signals-Community!